Comparative Pharmacology
Head-to-head clinical analysis: AMBIEN CR versus NOLUDAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBIEN CR versus NOLUDAR.
AMBIEN CR vs NOLUDAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AMBIEN CR's active ingredient is zolpidem, a non-benzodiazepine hypnotic that binds selectively to the benzodiazepine-1 (BZ1) receptor subtype on the GABA-A receptor complex, potentiating GABAergic inhibition and promoting sleep.
Barbiturate that enhances GABA-A receptor activity by prolonging chloride channel opening, leading to CNS depression.
12.5 mg orally once daily immediately before bedtime; lower dose of 6.25 mg may be considered. Not to exceed 12.5 mg per day.
250-500 mg orally at bedtime, with a maximum dose of 1000 mg daily.
None Documented
None Documented
Zolpidem immediate-release: ~2.5 h (range 1.4–3.8 h); modified-release (Ambien CR): ~2.8 h (range 1.6–4.5 h). Clinical note: Half-life increased in hepatic impairment and elderly.
25-35 hours
Primarily renal (80% as metabolites, <5% unchanged), minor fecal (<10%)
Primarily renal as metabolites; <5% unchanged. Biliary/fecal elimination is negligible.
Category C
Category C
Sedative-Hypnotic
Sedative-Hypnotic